Crinetics Pharmaceuticals CRNX Private company shares received under licensing arrangements
Private company shares received under licensing arrangements at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:SharesReceivedUnderLicensingArrangements.
The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's private company shares received under licensing arrangements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's private company shares received under licensing arrangements?
- Crinetics Pharmaceuticals (CRNX) reported private company shares received under licensing arrangements of $0 in Q4 2025.
- What is the long-term trend for Crinetics Pharmaceuticals's private company shares received under licensing arrangements?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's private company shares received under licensing arrangements has grown at a -100.0% compound annual growth rate (CAGR), from $2M to $0.
- What does private company shares received under licensing arrangements mean?
- This represents the non-cash receipt of equity securities in other companies as consideration for granting intellectual property or licensing rights. It indicates the value captured through strategic collaborations that is settled in equity rather than cash. This metric is vital for assessing the long-term value of a company's intellectual property portfolio.